CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Flow cell sorting followed by PCR-based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia.
Flow cell sorting followed by PCR-based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们证明了联合方法(细胞分选与基于 PCR 的克隆性评估)用于验证 ALL 中 MFC 检测结果的可能性。
我们获得了37例患者共38份生物样本的可疑MFC结果。通过流式细胞分选共分离42个细胞群体,随后开展多重PCR分析。大多数患者(n=29)患B细胞前体ALL,并接受可测量残留病(MRD)评估;其中79%接受CD19靶向治疗(blinatumomab或CAR-T)。
我们确认40个细胞群体具有克隆性(95.2%)。采用该技术,我们确认了极低水平MRD(MFC-MRD<0.01%)。我们还将其用于若干诊断样本的疑难结果,包括混合表型急性白血病,所得结果影响了最终诊断。
本研究展示了通过联合细胞分选和基于PCR的克隆性评估,验证ALL中MFC结果的可行性。该技术易于纳入诊断和监测流程,无需分离大量细胞,也无需预先了解个体克隆重排情况。我们认为,这一方法可为后续治疗提供重要信息。
We obtained questionable MFC results for 38 biological samples from 37 patients. In total, 42 cell populations were isolated by flow cell sorting for downstream multiplex PCR. Most of the patients (n = 29) had B-cell precursor ALL and were investigated for measurable residual disease (MRD); 79% of them received CD19-directed therapy (blinatumomab or CAR-T).
We established the clonal nature of 40 cell populations (95.2%). By using this technique, we confirmed very low MRD levels (<0.01% MFC-MRD). We also applied it to several ambiguous findings for diagnostic samples, including those with mixed-phenotype acute leukemia, and the results obtained impacted the final diagnosis.
We have demonstrated possibilities of a combined approach (cell sorting and PCR-based clonality assessment) to validate MFC findings in ALL. The technique is easy to implement in diagnostic and monitoring workflows, as it does not require isolation of a large number of cells and knowledge of individual clonal rearrangements. We believe it provides important information for further treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。